Literature DB >> 22533368

Tissue microarray analysis reveals protein expression patterns and potential biomarkers of clinical benefit to bortezomib in relapsed/refractory non-Hodgkin lymphoma.

John Gerecitano1,2, Sivaraman Gounder3, Julie Teruya-Feldstein4, Maria Arcila4, Shahiba Ogilvie4, Camille Gonzalez4, Dorothy Lin1,2, Junting Zheng5, Zhigang Zhang5, Alice McDonald6, George Mulligan6, Owen A O'Connor7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22533368     DOI： 10.1111/j.1365-2141.2012.09137.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  2 in total

1.  EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.

Authors:  Maria E Arcila; Khedoudja Nafa; Jamie E Chaft; Natasha Rekhtman; Christopher Lau; Boris A Reva; Maureen F Zakowski; Mark G Kris; Marc Ladanyi
Journal:  Mol Cancer Ther       Date:  2013-01-31       Impact factor: 6.261

Review 2.  The new concepts on overcoming drug resistance in lung cancer.

Authors:  Weisan Zhang; Ping Lei; Xifeng Dong; Cuiping Xu
Journal:  Drug Des Devel Ther       Date:  2014-06-06       Impact factor: 4.162
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.